But the sudden loss of efficacy of the recombinant IL‐1 receptor antagonist anakinra and the partial effect of the anti‐IL‐1 monoclonal antibody canakinumab suggest that the disease is not as IL‐1 dependent as classical auto‐inflammatory syndromes. Here, IL1B is linked to autoinflammatory syndrome.